Navigation Links
Stem Cell Assurance Announces Hiring of Vice President of Research and Development

JUPITER, Fla., April 13, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (SCLZ) has announced that Francisco J. Silva has been hired as its Vice President of Research and Development. Mr. Silva is expected to play a key role in leading the company's laboratory biological tool initiative and by developing a product portfolio targeted to meet the demands of large pharmaceutical companies' drug discovery and development platforms.  

Since 2007, Mr. Silva has served as CEO of DV Biologics LLC, and as President of DV Biosciences LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applications.  Mr. Silva's experience includes a previous position as VP of Research and Development for PrimeGen Biotech LLC, where he was responsible for developing the company's cell based platforms.  He has held teaching positions at Cal State Polytechnic University and was a reviewer for the Cell Transplantation journal.  He is also a published author and presenter on the subject of stem cells, is a member of the International Society of Cell Therapy Cell Commercialization Committee, and holds multiple stem cell patents.

Mark Weinreb, CEO of Stem Cell Assurance, said, "We are very pleased to welcome Mr. Silva to the Stem Cell Assurance team, bringing with him an accomplished scientific career.  His leadership within the biological tool field allows for the Company to utilize his contacts and skills for potential near term revenue while the company develops its long term growth plan."  

Mr. Silva commented, "I'm very excited about joining Stem Cell Assurance and to help the Company begin its path to developing new and innovative cell-based opportunities and technology.  I look forward to establishing a world class laboratory to expand our stem cell development and therapeutic programs, in addition to developing intellectual property."  

About Stem Cell Assurance, Inc.

Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications.  The Company also operates a wholly-owned subsidiary, Stem Cellutrition™, which plans to offers facial creams and other skin care products.


Mark Weinreb


Tel: (561) 904-6070

Fax: (561) 429-5684

SOURCE Stem Cell Assurance, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
2. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
3. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
4. Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance
5. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
6. Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman
7. Stem Cell Assurance Announces Appointment of Mark Weinreb, M.S. as Chief Executive Officer and Board Member
8. Stem Cell Assurance to Open New Laboratory Facility in Jupiter, Florida
9. Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November ... NeuroRehabilitation (ECNR) in Vienna, Austria ... European Congress of NeuroRehabilitation (ECNR) in Vienna, ... --> NovaVision, a wholly owned subsidiary of Vycor Medical, ... version of its Internet-delivered NovaVision Therapy Suite at the ...
(Date:11/30/2015)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer of ... its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded ... Office of the Chief Scientist (OCS). This grant, ... to Brainstorm for 2015 activities to approximately $1.8 million (approximately ...
(Date:11/27/2015)... ... 27, 2015 , ... Pittcon is pleased to announce the ... in symposia, oral sessions, workshops, awards, and posters. The core of the ... such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, ...
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):